Consistent with this, we have recently shown that serial TIL infusions promoted tumor infiltration of TIL-derived CD8+ clonotypes and led to complete disease remission in glioblastoma (22), indicating that repeated dosing may improve the pharmacokinetics and pharmacodynamics of TIL therapy and help drive clinical responses. The gene discussed is CD8A; the disease is glioblastoma.